is tirzepatide going off market A Major GLP-1 Drug Shortage Over. Some Patients Aren't Celebrating Lilly's tirzepatide and Novo Nordisk's

Semaglutide has shown promising effects on cholesterol levels, triglycerides, and other cardiovascular risk factors, helping to create a healthier metabolic profile for those at risk of heart disease

Metabolic rate increases slightly, so calorie expenditure rises

Segregation of amphetamine reward and locomotor stimulation between nucleus accumbens medial shell and core

USD 33.5 billion absolute opportunity by 2036, led by the United States and the United Kingdom

Per-lot CoAs and consistent specification support reproducibility across experiments

Approved by the FDA for type 2 diabetes management, tirzepatide has shown promising results in clinical trials, not only improving glycemic control but also contributing to significant weight reduction